Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancerGlobeNewsWire • 06/18/20
Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020GlobeNewsWire • 06/13/20
Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)GlobeNewsWire • 06/12/20
Roche's shares rise on news of study testing Actemra, remdesivir in COVID-19 patientsMarket Watch • 05/28/20
Analog Devices, Inc. (ADI) CEO Vincent Roche on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/20/20